nutex health inc - NUTX
NUTX
Close Chg Chg %
100.38 -5.52 -5.50%
Closed Market
94.86
-5.52 (5.50%)
Volume: 162.12K
Last Updated:
Mar 26, 2026, 4:00 PM EDT
Company Overview: nutex health inc - NUTX
NUTX Key Data
| Open $99.79 | Day Range 94.31 - 102.99 |
| 52 Week Range 45.88 - 193.07 | Market Cap $699.48M |
| Shares Outstanding 6.97M | Public Float 5.01M |
| Beta 0.03 | Rev. Per Employee N/A |
| P/E Ratio 9.58 | EPS $10.74 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 232.26K |
NUTX Performance
| 1 Week | 12.80% | ||
| 1 Month | -9.13% | ||
| 3 Months | -43.18% | ||
| 1 Year | 94.23% | ||
| 5 Years | -73.23% |
NUTX Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
3
Full Ratings ➔
About nutex health inc - NUTX
Nutex Health, Inc. engages in the management and operation of healthcare facilities. It operates through the following segments: Hospital Division, Population Health Management Division, and Real State Division. The Hospital Division is involved in developing and operating a network of micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). The Population Health Division establishes and operates provider networks such as independent physician associations (IPAs). The Real State Division owns land and hospital buildings which are leased to hospital entities. The company was founded in 2011 and is headquartered in Houston, TX.
NUTX At a Glance
Nutex Health, Inc.
1776 Yorktown Street
Houston, Texas 77056
| Phone | 1-713-660-0557 | Revenue | 875.26M | |
| Industry | Medical/Nursing Services | Net Income | 70.79M | |
| Sector | Health Services | 2025 Sales Growth | 82.365% | |
| Fiscal Year-end | 12 / 2026 | Employees | 944 | |
| View SEC Filings |
NUTX Valuation
| P/E Current | 9.58 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 15.711 |
| Price to Sales Ratio | 1.271 |
| Price to Book Ratio | 3.541 |
| Price to Cash Flow Ratio | 4.48 |
| Enterprise Value to EBITDA | 4.632 |
| Enterprise Value to Sales | 1.567 |
| Total Debt to Enterprise Value | 0.256 |
NUTX Efficiency
| Revenue/Employee | 927,179.025 |
| Income Per Employee | 74,988.347 |
| Receivables Turnover | 2.69 |
| Total Asset Turnover | 1.02 |
NUTX Liquidity
| Current Ratio | 3.412 |
| Quick Ratio | 3.394 |
| Cash Ratio | 1.177 |
NUTX Profitability
| Gross Margin | 50.76 |
| Operating Margin | 31.491 |
| Pretax Margin | 27.967 |
| Net Margin | 8.088 |
| Return on Assets | 8.25 |
| Return on Equity | 30.652 |
| Return on Total Capital | 10.397 |
| Return on Invested Capital | 12.841 |
NUTX Capital Structure
| Total Debt to Total Equity | 106.661 |
| Total Debt to Total Capital | 51.612 |
| Total Debt to Total Assets | 35.343 |
| Long-Term Debt to Equity | 99.587 |
| Long-Term Debt to Total Capital | 48.189 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Nutex Health Inc - NUTX
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 219.29M | 247.65M | 479.95M | 875.26M | |
Sales Growth
| +1,066.84% | +12.93% | +93.80% | +82.36% | |
Cost of Goods Sold (COGS) incl D&A
| 205.84M | 212.87M | 283.69M | 430.98M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 13.20M | 17.59M | 18.97M | 20.53M | |
Depreciation
| 12.04M | 15.99M | 17.47M | 19.23M | |
Amortization of Intangibles
| 1.16M | 1.60M | 1.50M | 1.30M | |
COGS Growth
| +1,243.25% | +3.42% | +33.27% | +51.92% | |
Gross Income
| 13.45M | 34.77M | 196.26M | 444.28M | |
Gross Income Growth
| +287.72% | +158.50% | +464.39% | +126.37% | |
Gross Profit Margin
| +6.13% | +14.04% | +40.89% | +50.76% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 18.03M | 36.07M | 58.48M | 168.66M | |
Research & Development
| - | - | - | - | - |
Other SG&A
| 18.03M | 36.07M | 58.48M | 168.66M | |
SGA Growth
| +44.39% | +100.02% | +62.15% | +188.41% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | 402.02M | 30.48M | 8.69M | |
EBIT after Unusual Expense
| (406.60M) | (31.77M) | 129.09M | 275.63M | |
Non Operating Income/Expense
| (559.30K) | (399.18K) | 668.93K | (8.62M) | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 12.49M | 16.32M | 19.93M | 22.23M | |
Interest Expense Growth
| +83.81% | +30.64% | +22.15% | +11.51% | |
Gross Interest Expense
| 12.49M | 16.32M | 19.93M | 22.23M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (419.65M) | (48.49M) | 109.83M | 244.78M | |
Pretax Income Growth
| -2,763.83% | +88.44% | +326.49% | +122.88% | |
Pretax Margin
| -191.36% | -19.58% | +22.88% | +27.97% | |
Income Tax
| 13.09M | (5.07M) | 15.02M | 64.42M | |
Income Tax - Current - Domestic
| 8.08M | 640.23K | 28.15M | 47.35M | |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| 5.01M | (5.71M) | (13.13M) | 17.08M | |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (432.74M) | (43.42M) | 94.81M | 180.36M | |
Minority Interest Expense
| (7.96M) | 2.36M | 42.71M | 109.57M | |
Net Income
| (424.78M) | (45.79M) | 52.10M | 70.79M | |
Net Income Growth
| -3,007.50% | +89.22% | +213.78% | +35.88% | |
Net Margin Growth
| -193.70% | -18.49% | +10.85% | +8.09% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (424.78M) | (45.79M) | 52.10M | 70.79M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (424.78M) | (45.79M) | 52.10M | 70.79M | |
EPS (Basic)
| -100.3605 | -10.386 | 10.2334 | 11.1278 | |
EPS (Basic) Growth
| -82.69% | +89.65% | +198.53% | +8.74% | |
Basic Shares Outstanding
| 4.23M | 4.41M | 5.09M | 6.36M | |
EPS (Diluted)
| -100.3605 | -10.386 | 9.6924 | 10.4778 | |
EPS (Diluted) Growth
| -82.69% | +89.65% | +193.32% | +8.10% | |
Diluted Shares Outstanding
| 4.23M | 4.41M | 5.49M | 6.76M | |
EBITDA
| 8.62M | 16.30M | 156.75M | 296.15M | |
EBITDA Growth
| +203.37% | +89.16% | +861.68% | +88.93% | |
EBITDA Margin
| +3.93% | +6.58% | +32.66% | +33.84% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 215.00 | |
| Number of Ratings | 3 | Current Quarters Estimate | 3.993 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | 15.41 | |
| Last Quarter’s Earnings | 1.693 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 10.48 | Next Fiscal Year Estimate | 17.555 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 3 | 3 | 3 | 2 |
| Mean Estimate | 3.99 | 3.61 | 15.41 | 17.56 |
| High Estimates | 5.02 | 4.75 | 19.78 | 19.49 |
| Low Estimate | 2.11 | 2.06 | 8.90 | 15.62 |
| Coefficient of Variance | 40.90 | 38.54 | 37.29 | 15.59 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 3 | 3 | 3 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Nutex Health Inc - NUTX
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Nutex Health Inc - NUTX
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 25, 2026 | Wesley Bamburg Chief Operating Officer | 2,411 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 24, 2026 | Warren Hosseinion President; Director | 7,765 | Open market or private purchase of non-derivative security Non-derivative transaction at $94.07 per share | 730,453.55 |
| Mar 24, 2026 | Warren Hosseinion President; Director | 12,465 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 24, 2026 | Frank E. Jaumot Director | 150 | Open market or private purchase of non-derivative security Non-derivative transaction at $93.56 per share | 14,034.00 |
| Mar 20, 2026 | Kelvin Spears Director | 32,137 | Open market or private purchase of non-derivative security Non-derivative transaction at $94.46 per share | 3,035,661.02 |
| Mar 20, 2026 | Kelvin Spears Director | 339 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 17, 2026 | Pamela W. Montgomery Chief Legal Officer-Healthcare | 4,441 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 17, 2026 | Pamela W. Montgomery Chief Legal Officer-Healthcare | 2,758 | Open market or private purchase of non-derivative security Non-derivative transaction at $88.87 per share | 245,103.46 |
| Apr 15, 2025 | Warren Hosseinion President; Director | 15,102 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 15, 2025 | Pamela W. Montgomery Chief Legal Officer-Healthcare | 1,371 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $72.1 per share | 98,849.10 |
| Apr 15, 2025 | Pamela W. Montgomery Chief Legal Officer-Healthcare | 1,637 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 15, 2025 | Josh deTillio Chief Operating Officer | 10,200 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 15, 2025 | Josh deTillio Chief Operating Officer | 6,481 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $72.1 per share | 467,280.10 |
| Apr 15, 2025 | Josh deTillio Chief Operating Officer | 6,933 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 15, 2025 | Jon C. Bates Chief Financial Officer | 6,500 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 15, 2025 | Jon C. Bates Chief Financial Officer | 4,888 | Open market or private purchase of non-derivative security Non-derivative transaction at $81.81 per share | 399,887.28 |
| Apr 15, 2025 | Jon C. Bates Chief Financial Officer | 3,888 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 15, 2025 | Jon C. Bates Chief Financial Officer | 2,388 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 15, 2025 | Elisa V. Luqman Chief Legal Officer - SEC | 5,000 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 15, 2025 | Elisa V. Luqman Chief Legal Officer - SEC | 1,070 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $72.1 per share | 77,147.00 |